Showing 20 of 86 recruiting trials for “Adult-onset myasthenia gravis”
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)
👨⚕️ Guiyun Cui, The Affiliated Hospital of Xuzhou Medical University📍 1 site📅 Started Mar 2026View details ↗
Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders
A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
Zilucoplan for Severe gMG Exacerbations
A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
👨⚕️ Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC📍 7 sites📅 Started Jan 2026View details ↗
RecruitingNCT07247279 ↗
Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
RecruitingNCT07294170 ↗
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis
RecruitingNCT07411963 ↗
Evaluation of the Condition of Patients Receiving EARLY Ravulizumab and Admitted in ICU for gMG Crisis
Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC Efgartigimod
Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
Enrolling by InvitationNCT07217509 ↗
PPDTM CorEvitasTM Myasthenia Gravis (MG) Drug Safety and Effectiveness Registry
RecruitingNCT06967480 ↗
Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis
GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)
A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases
🏥 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology📍 3 sites📅 Started Jun 2025View details ↗
Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases
Page 1 of 5Next →
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →